KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EBIT: 2017-2025

Historic EBIT for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -$260.0 million.

  • Moderna's EBIT fell 271.43% to -$260.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.5 billion, marking a year-over-year decrease of 28.59%. This contributed to the annual value of -$3.9 billion for FY2024, which is 6.94% up from last year.
  • According to the latest figures from Q3 2025, Moderna's EBIT is -$260.0 million, which was up 71.33% from -$907.0 million recorded in Q2 2025.
  • In the past 5 years, Moderna's EBIT ranged from a high of $5.4 billion in Q4 2021 and a low of -$2.0 billion during Q3 2023.
  • In the last 3 years, Moderna's EBIT had a median value of -$1.1 billion in 2025 and averaged -$945.5 million.
  • In the last 5 years, Moderna's EBIT skyrocketed by 2,609.84% in 2021 and then slumped by 20,866.67% in 2024.
  • Quarterly analysis of 5 years shows Moderna's EBIT stood at $5.4 billion in 2021, then crashed by 70.79% to $1.6 billion in 2022, then plummeted by 99.62% to $6.0 million in 2023, then slumped by 20,866.67% to -$1.2 billion in 2024, then plummeted by 271.43% to -$260.0 million in 2025.
  • Its last three reported values are -$260.0 million in Q3 2025, -$907.0 million for Q2 2025, and -$1.1 billion during Q1 2025.